Molecular Reproductive Medicine Unit, Department of Translational Medicine, Lund University, CRC Building 91, Plan 10, Jan Waldenströms Gata 35, SE-205 02, Malmö, Sweden.
Department of Oncology, Skane University Hospital, Malmö and Lund, Sweden.
Osteoporos Int. 2020 Jul;31(7):1261-1272. doi: 10.1007/s00198-020-05285-4. Epub 2020 Feb 1.
We investigated if bone mineral density was related to testosterone deficiency and/or previous cancer treatment in men who were childhood cancer survivors. Men with untreated testosterone deficiency or previous treatment with cranial irradiation were at increased risk of impaired bone health. Prevention of osteoporosis should be considered in their follow-up.
Childhood cancer survivors (CCS) are at increased risk of hypogonadism. Reduced bone mineral density (BMD) has been reported in CCS but it is unclear whether this is due to hypogonadism or a direct effect of cancer therapy. This study investigated BMD in CCS, and association with hypogonadism, previous treatment and cancer type.
Investigation of 125 CCS (median age 33.7 at inclusion; 9.6 at diagnosis) and 125 age-matched population controls. Serum testosterone and luteinizing hormone were assayed and BMD at total hip and lumbar spine L1-L4 measured. The mean difference in BMD (g/cm; 95% CI) between CCS and controls was analysed. Odds ratios (OR; 95% CI) for low BMD were also calculated.
Overall, BMD in the CCS cohort did not significantly differ from controls. However, compared with eugonadal CCS, the CCS with untreated hypogonadism had lower BMD at the hip (mean difference - 0.139 (- 0.210; - 0.067); p < 0.001) and spine (- 0.102 (- 0.174; - 0.030); p = 0.006). They also had a higher risk of low hip BMD (OR 4.1 (1.3; 14); p = 0.018). CCS treated with cranial irradiation also had lower BMD (hip - 0.076 (- 0.133; - 0.019); p = 0.009; spine - 0.071 (- 0.124; - 0.018); p = 0.009) compared with controls. The latter associations remained statistically significant after adjustment for hypogonadism.
CCS with hypogonadism or previously treated with cranial irradiation are at increased risk of impaired bone health. Prevention of osteoporosis should be considered as an important part in future follow-up of these men.
研究男性童年癌症幸存者的骨密度是否与睾丸激素缺乏和/或既往癌症治疗有关。未经治疗的睾丸激素缺乏或先前接受颅照射的男性发生骨健康受损的风险增加。应考虑在其随访中预防骨质疏松症。
童年癌症幸存者(CCS)患有性腺功能减退症的风险增加。CCS 患者的骨矿物质密度(BMD)降低已有报道,但尚不清楚这是由于性腺功能减退症还是癌症治疗的直接影响。本研究调查了 CCS 的 BMD 及其与性腺功能减退症、既往治疗和癌症类型的关系。
纳入了 125 名 CCS(中位年龄为 33.7 岁,诊断时为 9.6 岁)和 125 名年龄匹配的人群对照。检测血清睾丸激素和黄体生成素,并测量全髋和腰椎 L1-L4 的 BMD。分析 CCS 和对照组之间 BMD(g/cm;95%CI)的平均差异。还计算了低 BMD 的比值比(OR;95%CI)。
总体而言,CCS 队列的 BMD 与对照组无显著差异。然而,与性腺功能正常的 CCS 相比,未经治疗的性腺功能减退症的 CCS 髋关节(平均差异-0.139(-0.210;-0.067);p<0.001)和脊柱(-0.102(-0.174;-0.030);p=0.006)的 BMD 更低。他们还存在髋部 BMD 降低的高风险(OR 4.1(1.3;14);p=0.018)。接受颅照射治疗的 CCS 髋关节的 BMD 也较低(-0.076(-0.133;-0.019);p=0.009),脊柱(-0.071(-0.124;-0.018);p=0.009)也低于对照组。在调整性腺功能减退症后,这些关联仍然具有统计学意义。
患有性腺功能减退症或先前接受颅照射治疗的 CCS 发生骨健康受损的风险增加。在这些男性的未来随访中,应考虑预防骨质疏松症作为重要的一部分。